NurExone Biologic (TSXV: NRX | OTCQB: NRXBF

Roughly 900,000 people around the world sustain a new acute spinal cord injury every year. About 18,000 of them are in the United States. The lifetime direct-care cost for a single patient often exceeds US$1 million. And in the entirety of modern medicine, there is not one approved treatment that can repair a damaged spinal cord.

For as long as there has been medicine, the central nervous system has been considered the tissue that does not come back. The best available care today manages the consequences of paralysis (the pressure sores, the urinary complications, the loss of muscle mass) but it does not restore the connections between the brain and the body. As the Christopher Reeve-Irvine Research Center has framed it, restoring function after spinal cord injury requires regenerating the connections that are broken.

That is the problem a small preclinical-stage Israeli biotech is trying to solve.

The company is NurExone Biologic (NRX on the TSX Venture, NRXBF on the U.S. OTCQB, J90 on the Frankfurt exchange). It is developing an exosome-based nanodrug called ExoPTEN, designed to work in a way no approved therapy on the market can. Human trials have not yet occurred. The company targets an IND submission (the filing that authorises the start of human clinical trials) in the first half of 2027. What has occurred is a preclinical evidence base in animal models that is unusual enough to have earned Orphan Drug Designations from both the FDA and the EMA.

Two facts that matter first

The first is who is behind the company.

Chairman and founder Yoram Drucker is a serial biotech entrepreneur who has co-founded multiple publicly traded companies in the same space, including Pluristem (now Pluri Inc.), BrainStorm Cell Therapeutics, and InnoCan Pharma. CEO Dr. Lior Shaltiel is a chemical engineer and pharmacologist specialising in drug delivery systems. The R&D Director, Dr. Tali Kizhner, spent more than fifteen years on CMC (chemistry, manufacturing and controls) at Protalix Biotherapeutics, including work on FDA-approved biologics. The Scientific Advisory Board includes senior physicians and researchers from Sheba Medical Center (ranked 8th globally by Newsweek in 2025) and the Technion.

Past success at other companies does not guarantee success at NurExone. What it does establish is that the people running this program have taken drug candidates through clinical development before.

The second is what "exosomes" actually are.

Exosomes are naturally occurring nanoparticles that the human body produces to send signals from one cell to another. They are one of the ways the body naturally moves molecular cargo (proteins, RNA, other small biomolecules) around. In the last decade, biotech researchers have learned to load exosomes with therapeutic payloads and use them as delivery vehicles. The COVID-era mRNA vaccines, which used lipid nanoparticles to get genetic material into cells at global scale, proved that nanoscale drug delivery works in the real world. Exosomes are a related but distinct approach, naturally produced by the body rather than synthetically assembled.

NurExone's platform, called ExoTherapy, loads exosomes with a therapeutic payload and administers them by a minimally invasive route. The payload in ExoPTEN is a small interfering RNA, or siRNA, which is a molecule that silences a specific gene. The gene it silences is called PTEN. In healthy tissue, PTEN acts as a brake on nerve regeneration. Silencing it temporarily, in theory, releases that brake and allows damaged nerves to regrow.

What the preclinical data suggests

The preclinical evidence base is what has taken NurExone from a research idea to a company with dual regulatory designations.

In animal models of complete spinal cord transection, where the cord is fully severed, intranasal ExoPTEN administration was associated with significant motor improvement, sensory recovery, faster urinary reflex recovery, and measurable nerve regeneration confirmed by structural and electrophysiological analysis. The route of administration matters. Preclinical delivery was via a minimally invasive intranasal method rather than surgical implantation.

In a separate animal model of optic nerve crush (which is used to mimic the nerve damage caused by glaucoma), ExoPTEN treatment was associated with approximately 75 percent functional recovery and restored retinal cell survival to near-healthy levels. A larger-scale preclinical study on the optic nerve indication is currently underway at Sheba Medical Center.

None of this is human data. The gap between preclinical animal results and human clinical outcomes in biotech is large, and the vast majority of preclinical candidates do not reach regulatory approval. But animal models of complete spinal cord transection do not usually produce results in this range at all, which is part of why the regulators have looked at the program the way they have.

The regulatory position

ExoPTEN holds Orphan Drug Designation from both the FDA (United States) and the EMA (European Union) for acute spinal cord injury. Orphan Drug Designation is granted to therapies targeting conditions affecting fewer than 200,000 patients in the U.S. It provides regulatory incentives including potential market exclusivity of seven years upon approval (in the U.S.), reduced regulatory fees, and access to specific grant funding channels.

Dual designations across the two largest pharmaceutical markets are unusual for a company of NurExone's size. They do not guarantee clinical success, regulatory approval, or commercial viability. What they do is confirm that both agencies see the underlying unmet need and the program's regulatory viability as legitimate.

The company's stated near-term regulatory objective is an IND (Investigational New Drug) submission in the first half of 2027.

What would make this not work

NurExone is a preclinical-stage biotech. The single most important fact about that stage is that the vast majority of preclinical drug candidates never reach regulatory approval. Failure at any point between IND filing and Phase 3 is the base case for the industry, not the exception.

Animal results do not translate cleanly to human outcomes. Preclinical efficacy in a spinal cord transection model may not reproduce in human trials. The IND submission may be delayed. Regulatory reviews may raise questions the company cannot resolve.

Orphan Drug Designation does not guarantee approval or market exclusivity. It only provides regulatory incentives if and when the therapy is approved.

NurExone has raised over US$20 million since inception and has approximately 90 million shares outstanding (as of December 2025). As with any pre-revenue biotech, future capital will be required. How that capital is structured (equity, partnership, non-dilutive grants, out-licensing) will shape per-share outcomes regardless of clinical progress.

The founders' and executives' prior work at other companies is evidence about the operators. It is not a guarantee of any specific outcome at NurExone.

These are the standard risks for a preclinical biotech story.

What happens next

An IND submission is targeted for the first half of 2027. A large-scale preclinical study of ExoPTEN in the optic nerve indication is expected to start soon at Sheba Medical Center. ExoTop, the company's U.S. subsidiary, is working toward near-term revenue from the sale of naïve (unmodified) exosomes into the biotech research supply chain. The recently granted patents in the United States, Europe and South Korea continue to strengthen the intellectual property position.

If those milestones land, NurExone stops being a preclinical Israeli biotech that most retail investors have never heard of. It becomes a small clinical-stage company with dual Orphan Drug Designations, a platform technology potentially applicable across multiple indications, a preclinical dataset in a field considered unsolvable, and a management group that has taken biotech companies through clinical development before.

The catalyst path is real. The risk is also real. Both need to be held in the same hand.

The tickers are NRX on the TSX Venture Exchange, NRXBF on the U.S. OTCQB, and J90 on the Frankfurt Stock Exchange. For additional information, visit nurexone.com or public filings on SEDAR+.

Disclaimer: This content has been paid for by NurExone Biologic Inc. The author is not a registered investment advisor or medical professional. NurExone's products are in the preclinical stage and have not been tested in humans or approved by any regulatory authority. All scientific claims, pipeline details, and company data referenced come from NurExone Biologic Inc.'s public disclosures, corporate presentations, and press releases. Preclinical results referenced are from animal studies and do not guarantee similar outcomes in humans. Orphan Drug Designations referenced provide regulatory incentives including potential market exclusivity upon approval but do not guarantee clinical success, regulatory approval, or commercial viability. References to prior work by the Chairman, CEO, or other team members at other companies (including Pluristem, BrainStorm Cell Therapeutics, InnoCan Pharma, and Protalix Biotherapeutics) are historical and are not an indication of future performance at NurExone Biologic. Investing in preclinical biotech companies involves significant risk, including the possible loss of all capital invested. The majority of preclinical drug candidates never achieve regulatory approval. Readers should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.